ID   DM6
AC   CVCL_6628
SY   DM-6; DM006; Duke Melanoma 6
DR   BTO; BTO_0002957
DR   cancercelllines; CVCL_6628
DR   Cosmic; 1477315
DR   GEO; GSM276737
DR   GEO; GSM1672064
DR   GEO; GSM1672081
DR   GEO; GSM1672089
DR   GEO; GSM1672109
DR   GEO; GSM1672123
DR   GEO; GSM1672130
DR   Millipore; SCC221
DR   Wikidata; Q54831242
RX   PubMed=2404572;
RX   PubMed=2785141;
RX   PubMed=10752474;
RX   PubMed=11520076;
RX   PubMed=14871852;
RX   PubMed=19147755;
RX   PubMed=21654344;
RX   PubMed=26405815;
RX   PubMed=26673621;
CC   From: Duke University Medical Center; Durham; USA.
CC   Characteristics: Pigmented.
CC   HLA typing: A*02:01; B*12,13; C*01,02 (PubMed=10752474).
CC   Microsatellite instability: Stable (MSS) (PubMed=19147755).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): Millipore=SCC221
ST   Amelogenin: X
ST   CSF1PO: 8,11
ST   D13S317: 13
ST   D16S539: 10,11
ST   D18S51: 12
ST   D21S11: 29,30
ST   D3S1358: 16,18
ST   D5S818: 12,13
ST   D7S820: 7,11
ST   D8S1179: 14
ST   FGA: 24,27,28
ST   Penta D: 10,12
ST   Penta E: 10,11
ST   TH01: 9
ST   TPOX: 9,11
ST   vWA: 17,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 20
//
RX   PubMed=2404572;
RA   Crowley N.J., Slingluff C.L. Jr., Darrow T.L., Seigler H.F.;
RT   "Generation of human autologous melanoma-specific cytotoxic T-cells
RT   using HLA-A2-matched allogeneic melanomas.";
RL   Cancer Res. 50:492-498(1990).
//
RX   PubMed=2785141; DOI=10.4049/jimmunol.142.9.3329;
RA   Darrow T.L., Slingluff C.L. Jr., Seigler H.F.;
RT   "The role of HLA class I antigens in recognition of melanoma cells by
RT   tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor
RT   antigens.";
RL   J. Immunol. 142:3329-3335(1989).
//
RX   PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162;
RA   Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D.,
RA   Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J.,
RA   Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F.,
RA   Darrow T.L., Engelhard V.H.;
RT   "Melanomas with concordant loss of multiple melanocytic
RT   differentiation proteins: immune escape that may be overcome by
RT   targeting unique or undefined antigens.";
RL   Cancer Immunol. Immunother. 48:661-672(2000).
//
RX   PubMed=11520076; DOI=10.1006/cimm.2001.1809;
RA   Zennadi R., Abdel-Wahab Z., Seigler H.F., Darrow T.L.;
RT   "Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells:
RT   requirement of both HLA-DR15 and Fas antigens on melanomas for their
RT   lysis by Th2 cells.";
RL   Cell. Immunol. 210:96-105(2001).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=19147755; DOI=10.1158/1078-0432.CCR-08-1916;
RA   Augustine C.K., Yoo J.S., Potti A., Yoshimoto Y., Zipfel P.A.,
RA   Friedman H.S., Nevins J.R., Ali-Osman F., Tyler D.S.;
RT   "Genomic and molecular profiling predicts response to temozolomide in
RT   melanoma.";
RL   Clin. Cancer Res. 15:502-510(2009).
//
RX   PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461;
RA   Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J.,
RA   Brautigan D.L., Slingluff C.L. Jr.;
RT   "Comprehensive analysis of receptor tyrosine kinase activation in
RT   human melanomas reveals autocrine signaling through IGF-1R.";
RL   Melanoma Res. 21:274-284(2011).
//
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. 3rd,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
//
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. 3rd, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
//